On the stock market since 2010, it operates in the world of health and science. It has 399 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 210% a year over the last 4 years. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 73% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 505% a year on average.
The average analyst price target is $76.50 — 39% above today’s price.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 31/100.
On our five-subject report card, TGTX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: TGTX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
Analysts’ average target sits above today’s price, yet the valuation grade (55/100) says the stock isn’t cheap.